AI
CRDL

Atria Investments’s Cardiol Therapeutics CRDL Stock Holding History

Atria Investments’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,436
Closed -$27.2K – 2045
2025
Q3 		$27.2K Sell
25,436
-70,906
-74% -$86K ﹤0.01% 2003
2025
Q2 		$131K Sell
96,342
-42,711
-31% -$49.7K ﹤0.01% 1953
2025
Q1 		$135K Buy
139,053
+3,162
+2% +$3.88K ﹤0.01% 1860
2024
Q4 		$174K Buy
+135,891
New +$229K ﹤0.01% 1802
2024
Q3 		– Sell
-11,165
Closed -$22.6K – 1921
2024
Q2 		$22.6K Buy
+11,165
New +$23.7K ﹤0.01% 1903

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Atria Investments's CRDL Position: Q4 2025 in Review

Atria Investments sold out of Cardiol Therapeutics (CRDL) in Q4 2025, closing a stake of 25,436 shares — an estimated $27.2K sold.

Atria Investments first reported a position in CRDL in Q2 2024 and held it in 5 quarters. The position peaked at $174K in Q4 2024. 41 funds tracked by Wall St. Rank hold CRDL as of Q4 2025.

  • Atria Investments reported no remaining Cardiol Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Atria Investments sold 25,436 Cardiol Therapeutics shares in Q4 2025, an estimated $27.2K.
  • Atria Investments first reported a position in Cardiol Therapeutics in Q2 2024 and held it in 5 quarters.
  • Atria Investments's Cardiol Therapeutics position peaked at $174K in Q4 2024.
  • 41 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q4 2025.

Based on Atria Investments's 13F filing for Q4 2025, filed 5 Feb 2026.